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Background: Hand, foot and mouth disease (HFMD) is usually caused by Enterovirus 71(EV71), and Coxsackievirus
A16 (CV-A16) in Guangzhou, the biggest city of South China. However, Coxsackievirus A6 (CV-A6) were observed
increased dramatically from 2010–2012.
Methods: In order to understand and to describe the epidemiologic and genetic characteristics of CV-A6,
specimens of 5482 suspected HFMD cases were collected and examined by real-time fluorescence PCR. All samples
positive for enteroviruses were analyzed by descriptive statistics. Phylogenetic analysis of CV-A6 based on the VP1
sequences was performed to investigate molecular and evolutionary characteristics.
Results: Coxsackievirus A6 increased dramatically from 9.04% in 2010 to 23.21% in 2012 and became one of the
main causative agents of HFMD in Guangzhou. CV-A6 attack rates were highest in one to two year olds (33.14%).
Typical clinic symptoms of CV-A6 HFMD include fever (589/720, 81.81%), maculopopular rash and vesicular
exanthema around the perioral area (408/720, 56.66%), intraoral (545/720, 75.69%), the buttock (395/720, 54.86%),
the trunk (244/720, 33.89%), the knee (188/720, 26.11%), and the dorsal aspects of hands (437/720, 60.69%). Phylogenetic
analysis showed the CV-A6 isolates in this study belonged to Cluster A1 and were similar to those found in Shanghai in
2011 and 2012 (JX495148, KC414735), Shenzhen in 2011 (JX473394), Japan in 2011 (AB649243, AB649246), France in
2010(HE572928), Thailand in 2012(JX556564) and Israel in 2012 and 2013(.KF991010, KF991012).
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Hand, foot and mouth disease (HFMD) is a common
epidemic causing childhood infection caused by entero-
viruses. The causative enteroviruses include Coxsackie-
virus A (2–8, 10, 12, 14, 16), Coxsackievirus B (2, 5) and
enterovirus (EV) 71. EV 71 and CV-A16 are the most
common. HFMD primarily afflicts infants and children
younger than 5 years. Primary symptoms are fever, rash or
herpes of the hand, feet and oral cavity. HFMD was first
described in 1957 by Seddon in New Zealand. In 1958,
CV-A16 was isolated by Robinson et al. in Canada [1]. In
1959, the disease was formally named HFMD. EV71 was
isolated in 1969 and determined to be a HFMD causing
agent in 1972 [2]. Since then, numerous EV71 and CV-
A16 caused HFMD outbreaks have been reported [3].* Correspondence: wangming@gzcdc.org.cn
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unless otherwise stated.In China the first case of HFMD was reported in
Shanghai in 1982, followed by reports in more than ten
provinces and cities, including Beijing, Hebei, Tianjin,
Shandong and Guangdong. These reports included several
outbreaks of epidemic proportions [4-6]. The etiology of
HFMD in China is similar to that described in many other
countries of Asia and the world. The major HFMD caus-
ing pathogen was CV-A16 in the 1980s and EV71 in the
1990s but caseloads remained low until 2008 when a
nationwide epidemic occurred. Subsequently HFMD
was named a C-class infectious disease by the national
government [7,8]. In Guangzhou, HFMD associated
morbidity is higher than the national average [9]. In
addition to high rates of EV71 and CV-A16 infections,
CV-A6 has also emerged as a major disease causing
strain based on our surveillance. In order to fully
understand the epidemic and to develop appropriate
control strategies, this paper analyzed the molecular
epidemiology and disease characteristics of HFMDThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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2010 to 2012.
Results and discussion
From January 2010 to December 2012, a total of 5482
suspected HFMD cases were identified, 4111 (75%) of
which were positive by the pan-EV test (pan EV fluores-
cent kit from Guangzhou Huayin Medical Technology
Inc.). Of the 4111 pan-EV positive cases, the most fre-
quently presented serotypes were EV71 (1443, 35.10%),
CV-A16 (1261, 30.67%), and CV-A6 (720, 17.51%) and
untyped enteroviruses (604, 14.69%). EV71 and CV-A16
co-infection cases were 83 (2.02 %).
Distribution of CV-A6 by year
HFMD cases were reported in every month except for
February, 2010 and January and March, 2011. The pro-
portion of CV-A6 infections increased each year from
9.04% (106/1173) in 2010 to 17.58% (212/1206) in 2011
and 23.21% (402/1732) in 2012. CV-A6 was the main
cause of autumn peaks in 2010 and 2012 respectively,
while distributed evenly from July to September and
reappeared in November, 2011. The proportion of
CV-A6 among the total enterovirus types attained peak
in November, 2012. Compared to EV71 and CV-A16,
the prevalent season for CV-A6 was warm season in
2010 and 2011, while was cool season in 2012 (Figure 1).
The predominant autumn pathogen switched from
CV-A6 in 2010 to CV-A16 in 2011, and switched to CV-
A6 again in 2012. The proportion of HFMD cases posi-
tive for enterovirus varied significantly between years, as
did the proportion of each serotype. The enterovirus
positive rate was 94.73% (1173/1243) in 2010, 58.85%
(1206/2049) in 2011 and 79.01% in 2012 (1732/2192).
EV71 and CV-A16 remained the most frequent sero-
types in each year. Conversely the proportion of other
EVs decreased each year from 24.72% (290/1173) in
2010 to 15.26% (184/1206) in 2011 and to 7.51% (130/
1732) in 2012. EV71 and CV-A16 co-infection increased














































































Figure 1 Monthly distribution of 720 CV-A6 isolates from 2010 to 201Distribution of CV-A6 infection and disease characteristics
Of the total 4111 pan-EV positive HFMD cases, 3547
(86.28%) patients were recorded with age and gender,
ranging from 1 month to 30 years (median: 2 years) and
1827(52.94%, 1827/3451) were male.
Among the patients positive for EVs, 77.54% were aged
between one and four. Significant differences in attack
rates for each EV serotype were observed for each age
group. CV-A6 (173/522, 33.14%) was most common in
children aged one to two, however EV71 (376/1281,
29.35%) and CV-A16 (376/1086, 34.62%) were most
common in children aged three to four (χ2 = 118.818,
P<0.05). The ratio of males to females positive for
CV-A6 was 1.72:1 and no significant difference for each
EV serotype (χ2 = 0.708,P>0.05, Table 1).
Typical Clinical signs and symptoms of HFMD caused
by CV-A6 were fever (560/720, 77.78%), vesicular erup-
tions around the perioral area (408/720, 56.66%),
intraoral (545/720, 75.69%), the buttock (395/720,
54.86%), the trunk (244/720, 33.89%), the knee (188/720,
26.11%), and the dorsal aspects of hands (437/720,
60.69%) in addition to the usual manifestation of skin
eruptions on the hands, feet, and mouth. (Figure 3) Ac-
cording to our follow up survey by phone, some recov-
ered patients had nail loss 1 month after initial
symptoms. Most cases of HFMD were self-limited and
only 8 of 31 severe cases were CV-A6 infection which
suffered from meningitis. None CV-A6 infected patient
died during 3 years. Other 23 severe cases were EV71
positive.
Phylogenetic analysis
The 344bp VP1 region (2561nt-2904nt, responding to
AY421764) were sequenced from CV-A6 isolates and 72
representative isolates were selected to perform phylogen-
etic analysis. Among those isolates, 43 were selected to
represent 22 clustered cases and outbreaks in different
locations and times, as well as 29 were selected from spor-
adic cases, including 8 severe infections (Additional file 1:
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Figure 2 Distribution of EVS types in hand-foot-mouth diseases patients during 2010 to 2012, Guangzhou.
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KF639926, KM262854-KM262889). The sequence of 38
additional isolates, representing the full CV-A6 geographic
and time diversity and previously reported isolates from
China and the world, were downloaded from GenBank
and were subjected to phylogenetic analysis together with
our isolates.
Across all three years the nucleic acid and deduced amino
acid homology of 72 CV-A6 subtypes was 89.25%~100%
and 92.92%~100%, respectively. The nucleic acid sequences
of 44 isolates from 2010 and 2011 had higher homology
(92.31~100% identity), whereas the nucleotide identities
between 2012 and 2010, 2012 and 2011 isolates were
89.91%~99.4% and 89.25%~100%, respectively. Mean-
while, the deduced amino acid identities of 2010 and
2011 (93.51%~100%) were also higher than that of 2011
and 2012 (92.92%~100%). All CV-A6 isolates of this
study belonged to cluster A1, similar to those found in
Shanghai 2011 and 2012, Shenzhen 2011, Thailand 2012,
Israel 2012 and 2013, Japan 2011 and France 2010. Our
isolates were not similar to those of Chongqing 2011,
Henan 2010–2011 and Shandong 2010, which were foundTable 1 The demographic of patients with different enterovir
Virus EV71 CV-A16
V-P P Consratio (%) M F P
Cons
ratio (%) M F P
Age
year
0- 219 69 5.39 43 26 46 4.24 33 13 3
1- 718 264 20.61 176 88 150 13.81 95 55 17
2- 714 270 21.08 173 97 208 19.15 123 85 11
3- 1063 376 29.35 245 131 376 34.62 229 147 11
4- 504 177 13.82 113 64 192 17.68 127 65 4
5- 163 64 5.00 37 27 61 5.62 40 21 1
≥6 166 61 4.76 33 28 53 4.88 30 23 1
Total 3547 1281 36.12 820 461 1086 30.62 677 409 52
Ratio (M/F) 1.78 1.66by colleagues in Shandong province from 2009–2011 [10],
neither to the isolates in Yunnan 2004 nor Yunnan 2010
which fell into cluster B in our analysis (Figure 4).
This epidemiological investigation and molecular
phylogenetic analysis indicate that the HFMD epidemic
of Guangzhou, is becoming more severe and dynamic in
terms of the number and types of causative EVs. In
2011, CV-A6 cases appeared primarily in the summer
(June-September). However, the CV-A6 outbreak-
periods were significantly different in both 2010 and
2012 and were focused in autumn and winter, with a
large peak in the winter of 2012. Since 2008, CV-A6 has
caused outbreaks in Spain, France, Finland, Israel, UK,
Japan, Singapore, USA and Taiwan [11-16]. From 2009,
numerous non-linked reports of infections caused by
CV-A2, CV-A4, CV-A5, CV-A6, CV-A9, CV-A10 CV-
B3 and CV-B5 have been released in Shandong, Henan,
Chongqing, Changchun and Qingdao [17-22]. However,
to our knowledge, this is the first time that CV-A6 was
found emerged dramatically as a predominant causative
pathogen of HFMD in a metropolis of China. And this
may suggest that other EVs, like CV-A6, could becomeuses infection from 2010 to 2012
CV-A6 EV71and CV-A16co-infection Untyped EV
Cons
ratio (%) M F P
Cons
ratio (%) M F P
Cons
ratio (%) M F
9 7.47 28 11 7 8.54 5 2 58 10.07 34 24
3 33.14 103 70 17 20.73 9 8 114 19.79 75 39
5 22.03 70 45 19 23.17 13 6 102 17.71 59 43
7 22.41 74 43 27 32.93 15 12 167 28.99 101 66
8 9.20 33 15 9 10.98 7 2 78 13.54 41 37
3 2.49 11 2 1 1.22 0 1 24 4.17 15 9
7 3.26 11 6 2 2.44 0 2 33 5.73 23 10
2 14.72 330 192 82 2.31 49 33 576 16.24 348 228
1.72 1.48 1.53
Figure 3 A 2-year-8-month-old boy experienced prominent skin eruption and vesicles with CV-A6 infection in Guangzhou, 2010–2012.
(A) Eruptions on his hand; (B) Eruptions on his foot(especially on his knees); (C) Eruptions around his mouth; (D) Eruption and vesicles on his buttocks.
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population and adaption to the local environment.
Additionally, CV-A6 attack rates were highest in one to
two year olds (33.14%), younger than EV71 and CV-A16
cases which had peak attack-rates in three to four year-
olds (29.35% and 34.62%, respectively). This CV-A6-
associated younger cohort poses a risk because youn-
ger children have low-resistance and auto-immunity
and may present with more complex symptoms. This
stresses the importance of maintained surveillance of
HFMD infection and education on the signs and symp-
toms of HFMD in younger children.
We found no phylogenetic explanation for the increase
in the number of CV-A6 cases in 2011 and 2012. However
we hypothesize that the lack of immunity to this serotype
in Guangzhou population contributed to the increased
caseload. Additionally, Guangzhou has a sub-tropical cli-
mate meaning that autumn and winter are relatively mild.
This likely allows the persistent transmission of some EV
serotypes, such as CV-A6 throughout the year.
The 8 VP1 sequences separated by the severity of symp-
toms infected with CV-A6 virus were also included in the
Cluster A1 with high homology (89.25%~100%) and were
mixed throughout the phylogenetic tree. This indicated
that differences in the VP1 region cannot account for dif-
ferences in severity of disease. Although all CV-A6 isolates
of this study were classified into cluster A1, the alignment
of 2010–2011 isolates showed a higher nucleic acid and
amino acid sequence homology than that of 2012. This
could suggest a slight evolutionary shift from 2010–2011
to 2012.
A retrospective analysis of the HFMD associated symp-
toms showed that although there were some severe cases,a majority of patients had a typical presentation with
symptoms including fever, upper respiratory tract symp-
toms, maculopapular rash and vesicular exanthema cover-
ing the hands, feet and mouth. Although no deaths
associated with CV-A6 infections was found, there were
still 8 (8/720, 1.11%) patients who were identified with
CV-A6 positive, non-bacterial meningitis. This suggests
that CV-A6 not only causes common HFMD but can also
severely affect the central nervous system. Different from
HFMD caused by EV71 or CV-A16, the patients infected
by CV-A6 had intraoral lesions and maculopapular on
knees obviously in our study.
The timing and presentation of CV-A6 outbreaks have
varied in different geographical regions, suggesting some
adaptability of the virus. In the Boston HFMD outbreak
caused by CV-A6 in the winter of 2012, perioral papules
and perirectal eruption exhibited as the characteristic
feature in patients [13]. But perirectal eruption was not
observed obviously in Finland series CVA6 outbreaks in
2008 and Taiwan CVA6 outbreak in 2010[13,23]. In our
study, perirectal eruption was not found visibly.
Similar to Taiwan surveillance from 2004–2009, dur-
ing which only 3 (2.4%) of the 141 inpatients with CV-6
infection had central nervous system involvement [24],
only 8 (8/720, 1.11%) of the 720 CV-A6 infectors had
meningitis and all recovered uneventfully in our present
study. However, an unusually severe outbreak in Nevada,
US occurred from November, 2011 to February, 2012 and
led to a 19% hospitalization rate [14]. Cases from the 2010
outbreaks in Spain and Finland presented with onycho-
madesis [11,23,25], and outbreaks in France (2010) and
Japan (2012) CV-A6 cases were also associated with her-
pangina and onychomadesis [12,13]. But unless specified,
Figure 4 Phylogenetic analysis of 72 Guangzhou CV-A6 isolates
from 2010–2012 (■ 2010 isolates ● 2011 isolates▲ 2012 iso-
lates ○2011 severe cases Δ 2012 severe cases) and 38 reference
isolates from other Chinese and international locations based on
partial VP1 nucleotide sequences. The dendrogram was generated
by the neighbor-joining method (bootstrap analysis with 1,000
pseudo replicate data sets) by Mega 5.0. Genotypes are shown to
the right of the tress and bootstrap values are shown at each major
node. The scale at the bottom indicates a measurement of relative
phylogenetic distance.
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1–2 months after infection. These diversities of HFMD
presentation demonstrate the importance of symptom
monitoring and the physicians should be aware of the
emerging pathogens.
An EV71 vaccine is now in stage 3 clinical trials and has
proven safe and efficacious for EV71 prevention. However,
there is no evidence that it will provide immunity to other
EVs such as CV-A16 and CV-A6 [26]. Our research shows
that there are many other non-EV71 HFMD-causing EVs
that should not be disregarded. Infections caused by more
recently detected serotypes such as CV-A6 are not only
on the rise but can be associated with severe symptoms.
Therefore, even if the EV71 vaccine is highly effective, the
number and severity of HFMD cases may not decrease
significantly. It is absolutely necessary that future vaccines
should target CV-A6, the potential major causative patho-
gen of HFMD. The molecular epidemiology of CV-A6
should also be enhanced as it is highly likely that this
virus will continue to contribute significantly to the
HFMD case load. Genetic information from various
geographical regions will help determine links to sever-
ity and pathogenecity as well as evidence for genetic
recombination events which could lead to further out-




Feces, stool, throat swabs and cerebrospinal fluid samples
were collected from HFMD cases presenting at Guangzhou
from 5 surveillance hospitals (Guangdong Women and
Children Hospital, Guangzhou Yuexiu District Children
Hospital, Zengcheng People’s Hospital, Guangzhou Huado
Distrit People’s Hospital, and Huangpu Branch of the First
Affiliated Hospital, Sun Yat-sen University) and 12 districts
CDCs in Guangzhou. Samples were stored at −20°C
and tested at the district level center for disease con-
trol and prevention in Guangzhou. From March 1st,
2010 to October 30th, 2012, 5482 samples were col-
lected. Among the specimens, 5 cerebrospinal fluid
specimens were collected from fatal cases, 31 speci-
mens were available from severe cases, including
throat swabs and stool, 5444 samples were from mild
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All patients (or the guardians of the children patients)
gave oral informed consent.
Pretreatment of the samples and extraction of nucleic acid
Feces (1.5-2g) and stool samples were dissolved in 2ml
physiological saline (75% NaCl) and vortexed for 10 min,
followed by centrifugation at 3,800 rcf/min for 5 min.
The supernatant was collected and used for RNA extrac-
tion. Throat and anal swabs were vortexed in 2ml
physiological saline, centrifuged and the supernatant was
used to extract RNA. RNA was extracted from 140 μL of
pretreated sample using the QIAamp Viral RNA Mini
Kit (Qiagen, Hilden, Germany) and eluted in 50 μL
elution buffer. Throat swab and cerebrospinal fluid
specimens were not pre-treated prior to extraction.
CV-A6 detection and genotyping
The collected samples were amplified using the pan EV
fluorescent kit (Guangzhou Huayin medical technology
Inc.) for enterovirus detection. A positive sample was de-
fined as any sample with a cycle threshold (Ct) value ≤35.
Positive samples were further sub-typed using an EV71/
CV-A16 RNA fluorescent PCR combo-test kit and a CV-
A6 fluorescent PCR kit (Guangzhou Huayin medical tech-
nology Inc.). All tests were performed with the 7500 Fast
Real-Time PCR system (Applied Biosystems, USA).
For genotyping CV-A6 isolates, the same RNA extracts
were used and RT-snPCR was performed on the partial
5’ region of the VP1 capsid protein, as described by Nix
[27] with minor modifications. The first cycle of amplifi-
cation was performed using the SuperScript® One-step
RT-PCR Kit (Invitrogen, USA) and 10 pmol of each
reverse transcription primer (AN32, AN33, AN34 and
AN35) and PCR primers (222, 224), 12.5μl 2xPCR reac-
tion buffer, 1μl SuperScript® RT/Platinum Taq buffer,
2.5 μl template and ddH2O to 25μl. Reaction conditions
were as follows: incubation at 50°C for 30 min; denatur-
ation at 94°C for 2 min; 30 cycles of denaturation at 94°C
for 30 s, annealing at 42°C for 30 s, and extension at 60°C
for 45 s; 10 cycles of denaturation at 94°C for 30 s, anneal-
ing at 50°C for 30 s, and extension at 68°C for 45 s; final
extension at 72°C for 10 min.
The second cycle of amplification was performed with
the PrimeScript One-Step RT-PCR kit (Takara, Japan),
1 μl of the RT-PCR product, 0.8 μl of the primer pair
AN88, AN89 (20 μM), 25 μl of a 2xPCR buffer, and
ddH20 up to 50 μl. Reaction conditions were as follows:
40 cycles of denaturation at 98°C for 10 s, annealing at
60°C for 20 s, and extension at 72°C for 35 s; final ex-
tension at 72°C for 7 min. After purification and collec-
tion, the correctly sized PCR products were purified
with QIAquick PCR Purification Kit (Qiagen, Hilden,
Germany). The amplicons were sequenced with primersAN233 and AN232 by using an ABI 3130 Genetic
Analyzer (Applied Biosystems, USA). Sequences were
confirmed using BLAST in NCBI.
Statistical analysis
Descriptive statistics were performed, and a database
was developed for the storage and analysis of study data.
The mobidity and constituent ratio were calculated and
analyzed by SPSS 13.0 and Microsoft Excel 2007. The
statistical differences between proportions were tested
by chi-squared test or non-parametric test. A P-value
<0.05 was regarded as statistically significant.
Analysis of pathogen evolution
Representative isolates were selected for VP1 nucleic
acid sequencing, following the method described above.
Sequence data for each isolate was formatted and com-
piled into contiguous segments using Editseq and Seq-
man programs (DNASTAR, Mdison, WI). Each virus
was analyzed for molecular evolution using Cluster W
((Mega5.0) and a phylogenetic tree was produced using
the neighbor joining (Mega5.0) method as described by
Oberste et al. Seventy-two CV-A6 VP1 sequences from the
present study and 38 VP1 sequences from CV-A6 isolates
available in the GenBank database were used and displayed
as a dendrogram containing 110 isolates. The robustness of
the analysis was confirmed by bootstrap analysis with 1,000
pseudo replicates. The sequences of EV71 strain BrCr
(U22521) was used as outgroup in the phylogenetic
analysis.
Ethics statement: Data was collected as part of govern-
ment mandated health surveillance and analyzed an-
onymously so ethical approval was not needed.
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